|
News
2008
April 10, 2008 – Collegium Pharmaceutical’s Partner, BTG, Reports Positive Results from First Study Investigating BGC20-0166 in Obstructive Sleep Apnea Patients
April 8, 2008 – Collegium Pharmaceutical Announces FDA Filing for AllerNase™, a Nasal Inhaled Steroid for the Treatment of Allergic Rhinitis
February 14, 2008 – Collegium Pharmaceutical Inc. Announces Notice of Allowance for U.S. Patent for its DETERx™ Abuse Deterrent Sustained Release Technology
2007
December 20, 2007 – Collegium Pharmaceutical Inc. Announces Final Study Results of its Successfully Completed Proof of Concept Study for its Abuse Deterrent Sustained Release Opioid Product
December 17, 2007 – Collegium Pharmaceutical to Advance its Allergic Rhinitis Product into Phase III Trials
December 6, 2007 – Onset Therapeutics Announces FDA Submission for Novel Product for Topical Treatment of Genital Warts
October 31, 2007 – Collegium Pharmaceutical Inc. Announces Successful Completion of Proof of Concept Study for its Abuse Deterrent Sustained Release Opioid Product
August 15, 2007 – Collegium Pharmaceutical Provides Update on Development of its Nasal Inhaled Steroid for Allergic Rhinitis
- Expects to file for FDA Approval by the end of 2007
July 12, 2007 – Collegium Pharmaceutical Inc. Announces FDA Acceptance of IND for its Abuse Deterrent Sustained Release Opioid Product
June 15, 2007 – Collegium Pharmaceutical Inc., Announces the Filing of IND for Abuse Deterrent Sustained Release Opioid Product
March 5, 2007 – Collegium Pharmaceutical Announces Successful Completion of Proof of Concept Clinical Trial for Novel Combination Allergic Rhinitis Product
2006
October 4, 2006 – Collegium Pharmaceutical Inc., Announces FDA Acceptance of IND for Novel Combination Allergic Rhinitis Product
June 6, 2006 – Collegium Pharmaceutical Announces the Achievement of Development Milestone Under the Agreement with Cypress Bioscience
2005
December 5, 2005 – Accentia Biopharmaceuticals Acquires Exclusive License for an Additional Late-Stage Respiratory Product™
July 26, 2005 – Collegium Pharmaceutical Inc., Announces the Launch of Exactacain™
April 20, 2005 – Collegium Pharmaceutical Inc. and United Research Laboratories/Mutual Pharmaceutical Company Announce Product Development Agreement
January 4, 2005 – Collegium Pharmaceutical Inc., HEALTHPOINT, Ltd Announce Licensing Agreement for Two Late Stage Products
2004
December 28, 2004 – HEALTHPOINT® Enters Licensing Agreement With Collegium for Two Late-Stage Topical Analgesics
September 28, 2004 – BTG Establishes Collaboration Agreement with Collegium Pharmaceutical to Develop Innovative Therapy for Sleep Apnea
September 23, 2004 – Collegium Pharmaceutical Inc. Receives Notice of Allowance for US Patent for Novel Dosage Form for Combination Products
June 17, 2004 – Collegium Pharmaceutical Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for Novel Anti-Histamine Combination
January 26, 2004 – Cypress Bioscience, Inc. Licenses Collegium Pharmaceutical's Milnacipran Patent Portfolio
2003
December 3, 2003 – Collegium Pharmaceutical Signs Agreement with Endo Pharmaceuticals to Develop Abuse Deterrent Pain Products
October 28, 2003 – Collegium Pharmaceutical Announces it has completed its Series A financing with venture capital firm, Boston Millennia Partners
October 9, 2003 – Collegium Pharmaceutical Announces Relocation to New Facility in Rhode Island
October 8, 2003 – Collegium Acquires Tri-Nasal® Nasal Spray for Allergic Rhinitis from Muro Pharmaceutical
June 5, 2003 – Collegium Pharmaceutical Obtains U.S. Patent Allowance for Bupropion Patch-Nicotine Kit to Treat Smoking Cessation
May 21, 2003 – Collegium Pharmaceutical is Granted U.S. Patent on Once Daily, Pulsatile Delivery of Antiarrhythmic Sotalol
January 10, 2003 – Collegium Pharmaceutical and Tufts University to Collaborate on Human Monoclonal Antibody Targeting Life-threatening Hemolytic Uremic Syndrome Caused by E. Coli Toxins
September 5, 2002 – Cypress Bioscience, Inc. Establishes Collaboration with Collegium Pharmaceutical Inc. to Develop Second Generation milnacipran
|
